Granted Patent B2

US 12,605,333 · App. 17/725,673 · Granted Apr 21, 2026

Inventors: Paras Rameshlal Jain (Dayton, NJ); Sachin Vasant Chaudhari (Marc Drive, NJ)

Assignee: Tris Pharma, Inc.

A61K9/0065A61K9/1623A61K9/1635A61K9/1652A61K9/1664A61K45/06

Abstract

Claims (29)

1 . An orally administrable drug powder composition which forms a gastro-retentive RAFT having at least two trigger pulses, the composition comprising:

(a) at least one drug in a first pulse release form which releases in less than about 3 hours, wherein the drug is a free base or acid active pharmaceutical ingredient, or a pharmaceutically acceptable salt, solvate or hydrate, thereof;

(b) at least one drug in a trigger release form which is the second pulse release form comprises a pH sigmoidal delayed trigger system or an erosion delayed trigger system, wherein the drug is a free base or acid active pharmaceutical ingredient, or a pharmaceutically acceptable salt, solvate or hydrate, thereof;

(c) a RAFT system comprising at least one crosslinkable polysaccharide or at least two ionic crosslinkable anionic polymers, at least one ionic crosslinking agent, and at least one non-toxic gas generating agent which reacts with acid in the stomach to generate a non-toxic gas; and

wherein following oral ingestion, the composition provides a self-assembling gastro-retentive RAFT having entrapped therein, the at least one drug in the first pulse system of (a), the at least one drug in the second pulse release form of (b), and the gas generated in situ by the non-toxic gas generating agent, thereby providing a floating gastro-retentive RAFT having a the first and second trigger pulse system which retains at least the drug in the second pulse release form in the stomach for at least about 3 hours,

provided that the composition does not include a gamma hydroxybutyrate, or a gamma hydroxybutyrate salt, hydrate, tautomer, or solvate, or complex thereof.

2 . The orally administrable powder composition according to claim 1 , wherein the RAFT has two or more different delayed trigger pulse releases.

3 . The orally administrable powder composition according to claim 1 , wherein the composition comprises two or more different drugs.

4 . The orally administrable powder composition according to claim 1 , wherein the RAFT comprises two or more different drugs.

5 . The orally administrable powder composition according to claim 1 , wherein the RAFT comprises the same drug in more than two different release forms.

6 . The orally administrable powder composition according to claim 1 , wherein the RAFT formed is initially at least 15 mm in size.

7 . The orally administrable powder composition according to claim 1 , wherein the composition comprises two or more different RAFT systems.

8 . The orally administrable drug composition according to claim 1 , wherein the crosslinkable polysaccharide is a galactomannan selected from guar gum, fenugreek gum, or locust bean gum and the at least one cross-linking agent is one or more of borax, glutaraldehyde, and/or zirconium.

9 . The orally administrable drug composition according to claim 1 , wherein the gas-generating agent is selected from carbonates or bicarbonates of an alkali or alkaline earth metal, sulfites, or combinations thereof, or combinations thereof with an acid source which create a gas-generating couple.

10 . The orally administrable drug composition according to claim 9 , wherein the carbonate or bicarbonate of an alkali or alkaline earth metal are selected from potassium carbonate, potassium bicarbonate, sodium carbonate, sodium bicarbonate, calcium carbonate, sodium glycine carbonate, magnesium carbonate, or aluminum carbonate.

11 . The orally administrable drug composition according to claim 1 , wherein the drug is useful for treating one or more of allergic rhinitis, rheumatoid arthritis and related disorders, asthma, cancer, cardiovascular disease, inflammatory disorders, or ulcers.

12 . The orally administrable drug composition according to claim 1 , wherein the second pulse release form of (b) comprises granules comprising: a pH sigmoidal delayed trigger system comprising at least one drug and one or more of: a reverse enteric coated organic acid, at least one pH-independent, water-insoluble, water-permeable diffusion barrier coating polymer, and a bulking agent, wherein the diffusion barrier coating polymer is in a coating layer over the at least one drug and excipients in the granules.

13 . The orally administrable drug composition according to claim 1 , wherein the second pulse release form of (b) comprises granules comprising: an erosion delayed trigger system comprising at least one drug and one or more of: at least one erosion barrier forming polymer, and a bulking agent, wherein at least one erosion barrier forming polymer is in a coating layer over the at least one drug and excipients in the granules.

14 . The orally administrable drug composition according to claim 1 , wherein the composition comprises at least a first ionic crosslinkable anionic polymer and a second, different, ionic crosslinkable anionic polymer which is independently crosslinked.

15 . The orally administrable drug composition according to claim 14 , wherein the two anionic crosslinkable anionic polymers are selected from sodium alginate, pectin, gellan gum, alginic acid, sodium carboxy methyl cellulose, or xanthan gum.

16 . The orally administrable drug composition according to claim 1 , wherein the composition comprises at least a first crosslinking agent for the first ionic crosslinkable anionic polymer.

17 . The orally administrable drug composition according to claim 16 , wherein the first crosslinking agent for the first ionic crosslinkable anionic polymer is selected from calcium carbonate, calcium chloride, calcium gluconate, magnesium salts, ferrous salts, ferric salts, aluminum salts, or zinc salts.

18 . An orally administrable drug powder composition which forms a gastro-retentive RAFT having at least two trigger pulses, the composition comprising:

(a) at least one drug in a first pulse release form which releases in less than about 3 hours, wherein the drug is a free base or acid active pharmaceutical ingredient, or a pharmaceutically acceptable salt, solvate or hydrate, thereof;

(b) at least one drug in a trigger release form which is the second pulse release form comprises swelling delayed trigger system, wherein the swelling delayed trigger system comprises granules comprising at least one pH-independent, water insoluble, water-permeable diffusion barrier coating, the drug, a gelling agent, a swelling enhancer, wherein the at least one water permeable diffusion barrier coating is in a coating layer, over the at least one drug, the gelling agent, the swelling enhancer and excipients in the granules, wherein the drug is a free base or acid active pharmaceutical ingredient, or a pharmaceutically acceptable salt, solvate or hydrate, thereof;

(c) a RAFT system comprising at least one crosslinkable polysaccharide or at least two ionic crosslinkable anionic polymers, at least one ionic crosslinking agent, and at least one non-toxic gas generating agent which reacts with acid in the stomach to generate a non-toxic gas; and

wherein following oral ingestion, the composition provides a self-assembling gastro-retentive RAFT having entrapped therein, the at least one drug in the first pulse system of (a), the at least one drug in the second pulse system of (b), and the gas generated in situ by the non-toxic gas generating agent, thereby providing a floating gastro-retentive RAFT having the first pulse system and the second pulse system which retains at least the drug in the second pulse release form in the stomach for at least about 3 hours,

provided that the composition does not include a gamma hydroxybutyrate, or a gamma hydroxybutyrate salt, hydrate, tautomer, or solvate, or complex thereof.

19 . The orally administrable drug powder composition of claim 18 , wherein the barrier coating in (b) comprises 5% w/w to about 80% w/w of the coated granules in (b).

Assignments (3)

Continuity (3)

References Cited (204)